Department of Pharmaceutical Sciences and Drug Research, Punjabi University, India.
Analyst. 2011 Dec 21;136(24):5218-28. doi: 10.1039/c1an15587c. Epub 2011 Oct 19.
The present study was designed to characterize the possible degradation products of toremifene under varied conditions as prescribed by ICH guidelines Q1A(R2). The forced degradation studies were conducted on toremifene citrate under the conditions of hydrolysis (acidic, basic and neutral), photolysis, oxidation and dry heat. The drug was found unstable to photolysis and hydrolysis in water and acidic media but stable to alkaline hydrolysis, peroxide oxidation and thermal degradation. In total fifteen degradation products (I-XV) were formed, which were resolved from each other and the drug on a C-18 column employing an isocratic elution method. A complete mass fragmentation pattern of the drug was established with the help of LC/ESI-MS/TOF to assist characterization of the degradation products. Of the fifteen products, six products III, IV, VII, VIII, XIV and XV were detected in LC-MS. The molecular masses of III, IV, VII and VIII were found to be the same i.e., 387, while those of XIV and XV were 389 and 403, respectively. Structures of these products were elucidated through comparison of their mass fragmentation patterns with the drug, which were proposed on the basis of accurate masses of the parent and fragment ions. These were characterized as (Z)-2-(2-(dimethylamino)ethyl)-4-(4-hydroxy-1,2-diphenylbut-1-enyl)phenol (III), (E)-2-(2-(dimethylamino)ethyl)-4-(4-hydroxy-1,2-diphenylbut-1-enyl)phenol (IV), (E)-4-(4-(2-(dimethylamino)ethoxy)phenyl)-3,4-diphenylbut-3-en-1-ol (VII), (Z)-4-(4-(2-(dimethylamino)ethoxy)phenyl)-3,4-diphenylbut-3-en-1-ol (VIII), 2-(4-(10-(2-chloroethyl)phenanthren-9-yl)phenoxy)-N-methylethanamine (XIV), and 2-(4-(10-(2-chloroethyl)phenanthren-9-yl)phenoxy)-N,N-dimethylethanamine (XV). Finally, a most plausible mechanistic explanation for degradation of the drug in different chemical environments is also proposed. The results of the study disclose six new degradation related impurities of the drug.
本研究旨在按照 ICH 指南 Q1A(R2)规定的条件,对托瑞米芬的可能降解产物进行特征描述。在强制降解研究中,对枸橼酸托瑞米芬在水解(酸、碱和中性)、光解、氧化和干热条件下进行了研究。该药物在水和酸性介质中对光解和水解不稳定,但对碱性水解、过氧化物氧化和热降解稳定。总共形成了十五个降解产物(I-XV),这些产物在 C-18 柱上采用等度洗脱法彼此分离,与药物分离。在 LC/ESI-MS/TOF 的帮助下,建立了药物的完整质谱裂解模式,以协助降解产物的特征描述。在十五个产物中,有六个产物 III、IV、VII、VIII、XIV 和 XV 在 LC-MS 中被检测到。III、IV、VII 和 VIII 的分子量相同,均为 387,而 XIV 和 XV 的分子量分别为 389 和 403。通过将这些产物的质谱裂解模式与药物进行比较,确定了这些产物的结构,这些产物是基于母体和碎片离子的精确质量提出的。这些产物被鉴定为(Z)-2-(2-(二甲氨基)乙基)-4-(4-羟基-1,2-二苯基丁-1-烯基)苯酚(III)、(E)-2-(2-(二甲氨基)乙基)-4-(4-羟基-1,2-二苯基丁-1-烯基)苯酚(IV)、(E)-4-(4-(2-(二甲氨基)乙氧基)苯基)-3,4-二苯基丁-3-烯-1-醇(VII)、(Z)-4-(4-(2-(二甲氨基)乙氧基)苯基)-3,4-二苯基丁-3-烯-1-醇(VIII)、2-(4-(10-(2-氯乙基)菲-9-基)苯氧基)-N-甲基乙胺(XIV)和 2-(4-(10-(2-氯乙基)菲-9-基)苯氧基)-N,N-二甲 基乙胺(XV)。最后,还提出了药物在不同化学环境中降解的最合理的机制解释。研究结果揭示了该药物的六种新的降解相关杂质。